ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...
Drug Target Review

Preclinical takeaways from the World ADC Conference London

Explore the World ADC Conference highlights on antibody-drug conjugates and their impact on cancer therapy and clinical ...
Daily Post Nigeria

‘ADC deliberately frustrating registration of ADA by INEC’ – Umar Ardo

A promoter of the All Democratic Alliance, ADA, Umar Ardo, has accused the leadership of the African Democratic Congress, ADC, of deliberately frustrating ...
Fierce Biotech

BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival

BioNTech and partner DualityBio are accelerating the development of their B7-H3 antibody-drug conjugate into a phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). | BioNTech and ...
Fierce Biotech

Bristol Myers' $800M ADC hits primary survival endpoints in phase 3 breast cancer trial

A Chinese phase 3 trial of Bristol Myers Squibb’s antibody-drug conjugate has hit its dual primary survival endpoints, ...